ADAR and B-cell non-Hodgkin lymphoma: Beyond this, our data suggest that different types of tumors can benefit from general ADAR1 inhibition (or perhaps specific inhibition of MAVS editing) via different mechanisms, i.e., either through an increase in inflammation within the TME (for solid tumors) or through a decrease in T cell exhaustion (for B cell lymphoma).